Reassessing SGLT2 Trials in HFpEF: When robustness and fragility coexist

Key Points

• Robustness in SGLT2 trials shows a mixed effectiveness on HFpEF outcomes while indicating fragility in certain patient subgroups.
• A key finding reveals that SGLT2 inhibitors may improve heart function, yet responses vary significantly across populations.
• Analysis across multiple trials examines how robustness and fragility balance the effectiveness of SGLT2 medications in treating HFpEF.
• This complexity calls for a nuanced approach to heart failure treatment strategies, emphasizing the need for tailored interventions.